You just read:

Blueprint Medicines Announces Part 1 Results from PIONEER Trial Showing Broad Activity of Avapritinib Across Measures of Mast Cell Burden, Clinical Outcomes and Quality of Life in Indolent Systemic Mastocytosis

News provided by

Blueprint Medicines Corporation

Mar 16, 2020, 07:00 ET